Filing Flows › Akebia Therapeutics (AKBA) › Q1 2026
Akebia Therapeutics (AKBA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Akebia Therapeutics (AKBA) reported revenue of $53.5M for the first quarter 2026 (Q1 2026), -7% from a year earlier and -7% from the quarter before. Operating margin was -8.8%, net loss $9.1M (16.9% of revenue).
Akebia Therapeutics, Q1 2026: revenue $53.5M (-7% year over year), operating margin -8.8%, net loss $9.1M, operating cash flow −$21.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $53.5M | -7% | -7% |
| Operating profit | −$4.7M | — | -135% |
| Net earnings | −$9.1M | — | -248% |
| Operating cash flow | −$21.2M | -168% | — |
What changed
Revenue was $53.5M in Q1 2026, down 7% year over year and down 7% from the previous quarter. Auryxia was the largest line at 68% of revenue. Auryxia lost $7.6M year over year (down 17%), 200% of the total change.
Operating costs exceeded revenue by $4.7M, an operating margin of -8.8%. Total costs grew 33% against a revenue fall of 7%. The fastest-growing cost line was Cost of revenue (+61%). The quarter ended with a net loss of $9.1M, narrower than the previous quarter's $12.2M loss.
Operating cash flow was −$21.2M. Non-cash charges added back $328K of depreciation and $3.7M of share-based compensation. Working capital and other items used $16.1M. Capital expenditures of $62K exceeded it, leaving free cash flow of −$21.3M.
Questions
What was Akebia Therapeutics' revenue in the first quarter 2026?
Akebia Therapeutics (AKBA) reported revenue of $53.5M for the first quarter 2026 (Q1 2026), -7% from a year earlier and -7% from the quarter before.
Was Akebia Therapeutics profitable in the first quarter 2026?
Operating loss was $4.7M (-8.8% of revenue) and net loss $9.1M.